UMC Health System Partners with Omnicell for Advanced Services Solutions to Streamline Medication Management and Enhance Clinical and Operational Outcomes|||

Combination of deject-based technology, 340B programme management, and EnlivenHealth®
patient engagement solutions volition bulldoze central initiatives for Texas-based health system

Mount VIEW, Calif.–(BUSINESS WIRE)–Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and adherence tools for health systems and pharmacies, today announced that UMC Health Arrangement (“UMC”) in Lubbock, Texas, has selected Omnicell’due south comprehensive portfolio of Advanced Services solutions to support primal pharmacy initiatives, including acute care, outpatient, retail, and 340B plan strategies.

UMC has signed a ten-year sole source agreement for Omnicell’s cloud-based portfolio of solutions, including cardinal pharmacy automation and bespeak of care dispensing systems. The partnership is as well expected to support UMC’south goals of expanding community pharmacy services through opportunities with Omnicell’due south 340B services and EnlivenHealth’s patient engagement solutions, helping UMC to drive operational efficiency beyond its continuum of care. More importantly, these solutions will empower pharmacy staff and clinicians to focus on higher value tasks that back up patient safety.

As a public hospital with a forty-year tenure supporting the Lubbock community, UMC has experienced an increase in demand for its services. According to U.S. Census data, Texas has i of the highest uninsured population rates – at 18.4 percent in 2019, nearly double the national average.1
Programs like the federal 340B Drug Pricing Plan and technology-enabled patient appointment solutions are intended to help better wellness outcomes for these underserved communities.

“At UMC, our elevation priority is patient safety and ensuring healthy outcomes for our community,” said John Lowe, vice president of Support Services at UMC Health Organisation. “Partnering with Omnicell, we are building an advanced pharmacy technology strategy that aligns with our vision to streamline and accelerate the pharmacy and nursing practice across our organization. Most importantly, nosotros are laying a technology foundation that will enable the all-time patient intendance.”

Popular:   CrowdStrike Reports Fourth Quarter and Fiscal Year 2022 Financial Results|||

UMC has embraced the industry-defined vision of the Democratic Pharmacy, a roadmap designed to develop a zero-error, fully automatic medication management infrastructure. Through automation, intelligence, and expert services, the Democratic Pharmacy is expected to drive functioning and outcomes, and empower clinicians to shift their focus from manual authoritative functions to patient support needs.

“As medication management becomes more circuitous, nosotros believe health systems need cease-to-end, deject-based solutions that will allow them to work smarter, while supporting rubber, efficient pharmacy care,” said Scott Seidelmann, executive vice president and main commercial officer at Omnicell. “Nosotros’re confident that Omnicell’s partnership with UMC will provide comprehensive solutions that bridge astute and ambulatory care to assistance enhance performance and that are designed to deliver the highest levels of patient rubber beyond the wellness system.”

Acquire more than about Omnicell’southward innovative arroyo to empowering clinicians through medication management at

About UMC

UMC Health System is a national award-winning health system comprised of over iv,600 team members and more than thirty care locations. We are proud to partner with Texas Tech Academy Wellness Sciences Center to provide the all-time care to West Texas and Eastern New Mexico. Whether you are managing a chronic condition, dealing with an unexpected illness, or but working to stay salubrious, nosotros are passionate about getting you well and helping you stay that way. At UMC, Our Passion is You.

Almost Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care commitment model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Healthcare facilities worldwide utilise Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the U.k. leverage Omnicell’s innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce plush hospital readmissions. To larn more, visit

Popular:   Snowflake Announces Intent to Acquire Streamlit to Empower Developers and Data Scientists to Mobilize the World’s Data|||

OMNICELL, the Omnicell logo, and ENLIVENHEALTH are registered trademarks of Omnicell, Inc. or 1 of its subsidiaries.

Frontwards-Looking Statements

Certain statements independent in this press release relate to future plans and expected benefits and objectives regarding Omnicell’south products and services, including expectations regarding Omnicell’s cloud-based primal chemist’s shop automation and point of intendance dispensing systems, its comprehensive portfolio of Advanced Services, Omnicell’s 340B programme direction services, and EnlivenHealth’s SaaS-based patient date solutions, besides as the transformation of the pharmacy intendance delivery model to the industry-defined vision of the Democratic Pharmacy (and whatever implied fiscal affect in connection with the foregoing). These statements are “forward-looking statements” inside the meaning of the Individual Securities Litigation Reform Act of 1995. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties some of which are beyond our command. These risks and uncertainties include, amid other things, (i) risks related to the ongoing COVID-19 pandemic (including new variants of the virus), (2) Omnicell’southward ability to take advantage of growth opportunities and develop and commercialize new solutions and heighten existing solutions, (three) continued and increased competition from electric current and time to come competitors in the medication management automation solutions market and the medication adherence solutions marketplace, (4) unfavorable general economic and market conditions or reduction in demand for our solutions, (v) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more than products and services on a subscription basis, and its ability to larn companies, businesses, or technologies and successfully integrate such acquisitions, (vi) any disruption in Omnicell’s data technology systems and breaches of information security or cyber-attacks on its systems or solutions, (vii) Omnicell’south power to protect its intellectual property, (viii) Omnicell’south ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) risks related to the availability and sources of raw materials and components or toll fluctuations, shortages, or interruptions of supply, (x) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, and (xi) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s near recent Annual Written report on Grade 10-K and subsequent quarterly reports on Class 10-Q, also as in Omnicell’southward other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), bachelor at Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to identify undue reliance on forward-looking statements. All forward-looking statements independent in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any frontward-looking statements, whether equally a result of changed circumstances, new data, hereafter events, or otherwise, except equally required by law.

Popular:   How Managed Service Providers can sell disaster recovery services


1 south.,national%20average%20of%209.2%20percent.